86 Recruiting Trials

Clinical Trials
for Cancer in Maine

86 clinical trials for Cancer are currently recruiting participants at study sites in Maine. Study-related care is provided at no cost.

86
Recruiting trials
77
Study sites
23
Cities
34
Industry-sponsored
26
Phase 2
53
Phase 3

Cancer clinical trials in Maine: what to expect

Cancer is the single largest area of clinical research, and nearly every recruiting cancer trial is written for one cancer type at one stage. Most test a new drug or combination against the current standard treatment: targeted medicines matched to a mutation found in the tumor, immunotherapies that help the immune system recognize cancer cells, antibody-drug conjugates and cell therapies. Others study surgery and radiation techniques, ways to reduce side effects, and screening or prevention in people at higher risk.

In Maine, recruiting cancer studies are concentrated in Scarborough, South Portland, Brewer and Sanford, with sites in 19 other cities. 34 of the 86 are run by a drug or device company, which usually means a larger study with travel reimbursement; the rest are academic or hospital-led.

Who cancer trials usually look for

Every listing names the cancer type and stage it enrolls, and most also state how many earlier treatments you may have had: some are for people newly diagnosed, many are for cancer that has come back or spread after a first treatment stopped working. Targeted-therapy trials require a specific result on tumor testing, which the site can arrange if it has not been done. Trials generally ask that you are well enough for daily activity (a "performance status" the doctor scores), that blood counts and liver and kidney function are adequate, and that a few weeks have passed since your last treatment.

Having advanced or metastatic cancer does not rule you out. A large share of recruiting trials are designed specifically for it.

What taking part involves

Screening reviews your pathology and scans, often with new blood work and sometimes a fresh biopsy. Treatment then follows a cycle, typically every two or three weeks, with scans every six to twelve weeks to measure the response. Early-phase trials have more frequent visits at the start. The study drug and study-specific tests are provided at no cost; standard care that you would receive anyway is usually billed to insurance as normal. A placebo on its own is rare in cancer trials: when there is one, it is added to the standard treatment, and the consent form says so.

Questions worth asking the study team

Whether the trial is randomized and what the comparison treatment is; what happens if the cancer grows during the study; whether you can keep receiving the drug afterward if it is working; how the trial fits with the plan your own oncologist has suggested; and what travel or lodging support is offered. Your oncologist can also refer you directly.

Showing 20 of 86 recruiting Cancer trials in Maine

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
PHASE3 Dothan, Alabama +4 sites NCT07611110
This trial is looking for men with advanced prostate cancer that hasn't responded to standard treatments. Participants will receive AZD2265 to see if it works better than standard care.
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
PHASE3 Phoenix, Arizona +4 sites NCT06170788
This trial is looking for adults with non-small cell lung cancer that is advanced and has specific characteristics. Participants will receive a combination of sacituzumab tirumotecan and pembrolizumab or pembrolizumab alone to see which treatment helps them live longer.
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
PHASE3 Little Rock, Arkansas +4 sites NCT06312137
This trial is looking for adults with a type of lung cancer called non-small cell lung cancer who did not have a complete response after surgery. Participants will receive medications to see if adding sacituzumab to pembrolizumab helps them stay cancer-free longer.
Recruiting
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
PHASE3 Homewood, Alabama +4 sites NCT06855277
This trial is looking for adult men with a specific type of prostate cancer called PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). Participants will receive a treatment called AAA817 along with other medications to see if it improves their condition.
Recruiting
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
PHASE3 Anchorage, Alaska +4 sites NCT07214779
This trial is looking for women with a specific type of ovarian cancer that hasn't responded to platinum-based treatments. Participants will receive the drug INCB123667 or a chemotherapy chosen by their doctor.
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
PHASE3 Birmingham, Alabama +4 sites NCT05633654
This trial is looking for adults with triple negative breast cancer that remains after surgery and treatment. Participants will receive an experimental treatment combining two medications after recovery from surgery.
Recruiting
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
PHASE3 Birmingham, Alabama +4 sites NCT05774951
This trial is looking for people with early breast cancer who have completed at least 2 years of standard treatment. Participants will receive camizestrant to see if it helps improve their outcomes compared to standard therapy.
Recruiting
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
PHASE3 Birmingham, Alabama +4 sites NCT06824467
This trial is looking for women with certain types of ovarian cancer who have had previous chemotherapy. Participants will receive a treatment to see if it helps them live longer without their cancer worsening.
Recruiting
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
PHASE3 Mobile, Alabama +4 sites NCT06952504
This trial is looking for people with advanced or recurring endometrial cancer that has specific characteristics. Participants will receive a combination of two medicines, sacituzumab tirumotecan and pembrolizumab, to see if it helps them live longer or keeps the cancer from worsening.
Recruiting
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
PHASE3 Chandler, Arizona +4 sites NCT07291037
This trial is looking for patients with advanced lung cancer that tests positive for a specific protein. Participants will receive either datopotamab deruxtecan or docetaxel as treatment.
Recruiting
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
PHASE3 Birmingham, Alabama +4 sites NCT07190248
This trial is looking for people with a type of lung cancer called non-small cell lung cancer. Participants will receive a combination of two treatments to see if they can help them live longer without the cancer getting worse.
Recruiting
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
PHASE3 Chandler, Arizona +4 sites NCT06377852
This trial is looking for older patients with metastatic breast cancer to test different dosing strategies for two medications. Participants will help researchers understand how well these strategies work and which might be better tolerated.
Recruiting
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
PHASE3 Phoenix, Arizona +4 sites NCT06876714
This trial is looking for adults with HER2-positive breast cancer who have no residual invasive disease after chemotherapy. Participants will receive either 6 or 12 months of HER2-targeted medications to see which duration works best.
Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
PHASE3 Fullerton, California +4 sites NCT06758401
This trial is looking for people with advanced lung cancer who have high levels of a specific protein called PD-L1. Participants will receive a combination treatment of two medications or just one and will be monitored regularly at a clinic.
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
PHASE3 Mobile, Alabama +4 sites NCT06627647
This trial is looking for adults with a specific type of lung cancer that has spread and has specific characteristics. Participants will receive one of two treatments combined with chemotherapy as part of their first treatment plan.
Recruiting
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
PHASE2 Anchorage, Alaska +4 sites NCT07063745
This trial is looking for people with advanced lung cancer who have a specific genetic change. Participants will receive either a combination of Navlimetostat, pembrolizumab, and chemotherapy or a placebo with the same treatments.
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
PHASE3 Hot Springs, Arkansas +4 sites NCT07085767
This trial is looking for adults with advanced breast cancer that hasn’t been treated before. Participants will receive palazestrant with ribociclib or letrozole with ribociclib to see which treatment works better.
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
PHASE3 Tucson, Arizona +4 sites NCT06692738
This trial is looking for adults with a specific type of lung cancer that has spread or is hard to treat. Participants will receive a combination of a new drug and chemotherapy as their first treatment.
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
PHASE3 Birmingham, Alabama +4 sites NCT05879926
This trial is looking for premenopausal women with early-stage breast cancer that is hormone receptor-positive. Participants will receive hormone therapy and may also get chemotherapy to see if it helps them live longer without cancer returning.
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
PHASE3 Tucson, Arizona +4 sites NCT07044336
This trial is looking for women with a specific type of advanced endometrial cancer that has not responded to previous treatments. Participants will receive either a new drug called puxitatug samrotecan or standard chemotherapy chosen by their doctor.
Recruiting

Where the Cancer studies are in Maine

  • MaineHealth Maine Medical Center- Scarborough, Scarborough27 trials
  • MaineHealth Cancer Care and IV Therapy - South Portland, South Portland23 trials
  • MaineHealth Cancer Care Center of York County, Sanford20 trials
  • Lafayette Family Cancer Center-EMMC, Brewer18 trials
  • Harold Alfond Center for Cancer Care, Augusta17 trials
  • MaineHealth Maine Medical Center - Portland, Portland13 trials

Counts are recruiting studies listing at least one site in Maine, from ClinicalTrials.gov, refreshed every two days.

Cancer clinical trials in Maine: common questions

How many Cancer clinical trials are recruiting in Maine?
TrialFinder currently lists 86 recruiting Cancer clinical trials with study sites in Maine. Results are updated regularly from ClinicalTrials.gov, the official U.S. registry of clinical studies.
Where are Cancer clinical trials located in Maine?
Sites for these Cancer trials are spread across Maine. Open any trial to see its full list of participating locations and contact details.
Do I need insurance to join a Cancer clinical trial in Maine?
No. Study-related care is covered by the trial sponsor at no cost to participants, including the study treatment, required lab tests and study visits. Many Cancer trials in Maine also compensate participants for time and travel. Health insurance is not required to search or enroll.
How do I qualify for a Cancer clinical trial in Maine?
Each study sets its own criteria based on age, Cancer diagnosis details, prior treatments, current medications and general health. The fastest way to find out is to contact a research site directly — most will pre-screen you by phone in 10 to 15 minutes at no charge. You can also create a free TrialFinder profile to be matched automatically.
Will I get a placebo instead of cancer treatment?
Almost never. Cancer trials compare a new treatment with the current standard treatment, or add the study drug to standard treatment. When a placebo is used it is on top of standard care, and the consent form states this before you decide.
Can I join a cancer trial if my cancer has spread?
Yes. Many recruiting cancer trials are written for advanced or metastatic disease, including people whose earlier treatments have stopped working. The listing states the stage and prior treatments it accepts.
Do I have to stop my current cancer treatment to join a trial?
It depends on the trial. Some enroll people whose current treatment has stopped working, some add the study drug to the treatment you are on, and some are for people who have not started treatment yet. Ask the study team before changing anything.
Are Clinical Trials Safe? What Patients Should Know
How clinical trial safety works — phases, IRB oversight, informed consent, and your right to withdraw — plus the real risks and questions to ask.
How to Know If You Qualify for a Clinical Trial
Every trial has eligibility criteria based on diagnosis, age, and medical history. Here's how to tell if you qualify — and what to do if you're not sure.
Clinical Trials Without Insurance: What You Need to Know
Clinical trials cover the cost of study-related care, making them one of the few ways to access treatment without health insurance. Here's what's covered.
All guides →

Check Your Eligibility

Create a free profile and our AI will match you to Cancer trials near you in Maine.

Get Matched — Free
No insurance required

Breast cancer trials test new chemotherapy regimens, immunotherapy combinations, targeted therapies, and early-detection methods across all stages of breast cancer.

All Cancer trials →